Product menu

SHINGRIX efficacy and safety profile data in adults aged ≥50 years and immunocompromised patients aged ≥18 years

SHINGRIX efficacy profile

  • In adults ≥50 years (ZOE-50 and ZOE-70)1,2
  • In the incidence of PHN in patients aged ≥70 years
  • In two immunocompromised patient populations aged ≥18 years vs. placebo

Learn more about SHINGRIX efficacy data

SHINGRIX safety profile

  • In adults aged ≥50 years, was extensively studied in two large Phase III clinical trials
  • In immunocompromised patients aged ≥18 years

Learn more about SHINGRIX safety profile data

Patient icon

Start the conversation about shingles risk with your patients

Nearly everyone ≥50 years old should be protected against shingles.2

Learn more
thunderbolt icon

Shingles pain can be severe, disabling, and last for weeks1

See how shingles pain could impact your patients.1

SHINGRIX is not indicated for the treatment of HZ or its complications, such as pain.

Learn more
Checkmark icon

Provide eligible patients your strong recommendation to vaccinate with SHINGRIX

Review the recommendations on the use of SHINGRIX by the National Advisory Committee on Immunization (NACI).2

Learn more

References:

  1. SHINGRIX Product Monograph. GlaxoSmithKline Inc., November 15, 2022.
  2. Public Health Agency of Canada. An Advisory Committee Statement (ACS), National Advisory Committee on Immunization (NACI) – Updated Recommendations on the Use of Herpes Zoster Vaccines. Ottawa, Ontario: Public Health Agency of Canada; June 2018. Available at: https://www.canada.ca/en/services/health/publications/healthy-living/updated-recommendations-use-herpes-zoster-vaccines.html. Accessed November 30, 2022.

Trademarks are owned by or licensed to the GSK group of companies.

©2024 GSK Group of companies or its licensor.

10572 | 05/24